Antibacterial quinazoline-4(3H)-one derivatives

1. A compound of formula I

wherein

R 1 is H or halogen;

R 2 is the group M;

R 3 is H or halogen;

M is one of the groups M A and M B represented below

wherein A represents a bond or C.C;

R 1A is H or halogen;

R 2A is H, (C 1 -C 3 )alkoxy or halogen;

R 3A is H, (C 1 -C 3 )alkoxy, hydroxy(C 2 -C 4 )alkoxy, hydroxy(C 1 -C 4 )alkyl, 1,2-dihydroxyethyl,

di(C 1 -C 3 )alkylamino, 1-hydroxymethyl-cycloprop-1-yl, 1-((dimethylglycyl)oxy)methyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, morpholin-4-yl-(C 1 -C 2 )alkyl or morpholin-4-yl(C 2 -C 3 )alkoxy; and

R 1B is hydroxy(C 1 -C 3 )alkyl, amino(C 1 -C 3 )alkyl, [di(C 1 -C 3 )alkylamino]-(C 1 -C 3 )alkyl, 1,2-dihydroxyprop-3-yl, 1-amino-cycloprop-1-yl, 1-hydroxymethyl-cycloprop-1-yl, 1-((phosphonooxy)methyl)cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, trans-2-aminomethyl-cycloprop-1-yl, 1-fluoro-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-1-methyl-cycloprop-1-yl, 2-fluoro-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-2-methyl-cycloprop-1-yl, 1-(1,2-dihydroxyethyl)-cycloprop-1-yl, trans-2-(1,2-dihydroxyethyl)-cycloprop-1-yl, 1-(hydroxymethyl)cyclobut-l-yl, 3-hydroxyoxetan-3-yl, 3-(hydroxy(C 1 -C 3 )alkyl)oxetan-3-yl, 3-hydroxythietan-3-yl, trans-(cis-3,4-dihydroxy)-cyclopent-1-yl, 3-(2-aminoacetamido)cyclopentyl, 3-hydroxymethylbicyclo[1,1,1]pentan-1-yl or 3-hydroxyoxetan-3-ylmethyl;

or a salt thereof.

2. The compound of formula I according to claim 1 , which is a compound of formula I CE

wherein

R 1 is H or halogen;

R 2 is the group M;

R 3 is H or halogen;

M is one of the groups M A and M B represented below

wherein A represents a bond or C.C;

R 1A is H or halogen;

R 2A is H, (C 1 -C 3 )alkoxy or halogen;

R 3A is H, (C 1 -C 3 )alkoxy, hydroxy(C 2 -C 4 )alkoxy, hydroxy(C 1 -C 4 )alkyl, 1,2-dihydroxyethyl, di(C 1 -C 3 )alkylamino, 1-hydroxymethyl-cycloprop-1-yl, 1-((dimethylglycyl)oxy)methyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, morpholin-4-yl-(C 1 -C 2 )alkyl or morpholin-4-yl(C 2 -C 3 )alkoxy; and

R 1B is hydroxy(C 1 -C 3 )alkyl, amino(C 1 -C 3 )alkyl, dimethylamino-(C 1 -C 3 )alkyl, 1,2-dihydroxyprop-3-yl, 1-amino-cycloprop-1-yl, 1-hydroxymethyl-cycloprop-1-yl, 1-((phosphonooxy)methyl)cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, trans-2-aminomethyl-cycloprop-1-yl, 1-fluoro-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-1-methyl-cycloprop-1-yl, 2-fluoro-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-2-methyl-cycloprop-1-yl, 1-(1,2-dihydroxyethyl)-cycloprop-1-yl, trans-2-(1,2-dihydroxyethyl)-cycloprop-1-yl, 1-(hydroxymethyl)cyclobut-l-yl, 3-hydroxyoxetan-3-yl, trans-(cis-3,4-dihydroxy)-cyclopent-1-yl, 3-(2-aminoacetamido)cyclopentyl, 3-hydroxymethylbicyclo[1,1,1]pentan-1-yl or 3-hydroxyoxetan-3-ylmethyl;

or a salt thereof.

3. The compound of formula I according to claim 1 , which is a compound of formula I P

wherein

R 1 is H or halogen;

R 2 is the group M;

R 3 is H or halogen;

M is one of the groups M A and M B represented below

wherein A represents a bond or C.C;

R 1A is H or halogen;

R 2A is H, (C 1 -C 3 )alkoxy or halogen;

R 3A is H, (C 1 -C 3 )alkoxy, hydroxy(C 2 -C 4 )alkoxy, hydroxy(C 1 -C 4 )alkyl, 1,2-dihydroxyethyl, di(C 1 -C 3 )alkylamino, 1-hydroxymethyl-cycloprop-1-yl, 1-((dimethylglycyl)oxy)methyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, morpholin-4-yl-(C 1 -C 2 )alkyl or morpholin-4-yl(C 2 -C 3 )alkoxy; and

R 1B is hydroxy(C 1 -C 3 )alkyl, amino(C 1 -C 3 )alkyl, 1,2-dihydroxyprop-3-yl, 1-amino-cycloprop-1-yl, 1-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, trans-2-aminomethyl-cycloprop-1 -yl, trans-2-hydroxymethyl-1-methyl-cycloprop-1-yl, trans-2-hydroxymethyl-2-methyl-cycloprop-1-yl, 1-(1,2-dihydroxyethyl)-cycloprop-1-yl, trans-2-(1,2-dihydroxyethyl)-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, 3-(hydroxy(C1-C3)alkyl)oxetan-3-yl, 3-hydroxythietan-3-yl, trans-(cis-3 ,4-dihyd roxy)-cyclopent- 1 -yl, 3-(2-aminoacetamido)cyclopentyl or 3-hydroxymethylbicyclo[1,1,1]pentan-1-yl;

or a salt thereof.

4. The compound of formula I according to claim 1 , wherein R 1 is H or fluorine, R 3 is H or fluorine, R 1A , when present, is H or fluorine and R 2A , when present, is H;

or a salt thereof.

5. The compound of formula I according to claim 1 , wherein R 1 is the group M A ;

or a salt thereof.

6. The compound of formula I according to claim 5 , wherein A represents a bond;

or a salt thereof.

7. The compound of formula I according to claim 5 , wherein A represents C.C;

or a salt thereof.

8. The compound of formula I according to claim 7 , wherein R 1A is H or fluorine, R 2A is H and R 3A is hydroxymethyl, 1,2-dihydroxyethyl or 3-hydroxyoxetan-3-yl;

or a salt thereof.

9. The compound of formula I according to claim 1 , wherein R 2 is the group M B ;

or a salt thereof.

10. The compound of formula I according to claim 1 ,

wherein R 2 is the group M B and R IB is 1-amino-cycloprop-1-yl, trans-2-hydroxymethyl-cycloprop-1-yl, 1-fluoro-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl- 1-methyl-cycloprop-1-yl, 2-fluoro-2-hydroxymethyl-cycloprop-1-yl, trans-2-hydroxymethyl-2-methyl-cycloprop-1-yl, trans-2-(1,2-dihydroxyethyl)-cycloprop-1-yl, trans-(cis-3,4-dihydroxy) -cyclopent-1-yl or 3-hydroxymethylbicyclo[1,1,1]pentan-1-yl;

or a salt thereof.

11. The compound of formula I according to claim 1 , wherein the compound includes:

(R)-4-(7-(2-fluoro-4-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(4-oxo-7-phenylquinazolin-3(4H)-yl)butanamide;

(R)-N-hydroxy-4-(7-(((1S,2S)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((3-hydroxyoxetan-3-yl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((1-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(5-amino-5-methylhexa-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((4-(2-hydroxyethyl)phenyl)ethynyl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(6-fluoro-7-(((1S,2)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-((R)-5,6-dihydroxyhexa-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(6-fluoro-7-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(6-fluoro-7-((1-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H) -yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((3-(hydroxymethyl)bicyclo[1.1.1]pentan-1-yl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((4-(2-hydroxyethoxy)phenyl)ethynyl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(((1s,3R,4S)-3,4-dihydroxycyclopentyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl) -N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((4-(1-(hydroxymethyl)cyclopropyl)phenyl)ethynyl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-(((1S,2R)-2-(hydroxymethyl)-2-methylcyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-((4-((R)-1,2-dihydroxyethyl)phenyl)ethynyl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(2R)-4-(7-((1-(1,2-dihydroxyethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-(((1R,2R)-2-(hydroxymethyl)-1-methylcyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(8-fluoro-7-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-(1-(4-((3-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-4-oxo-3,4-dihydroquinazolin-7-yl)ethynyl)phenyl)cyclopropyl)methyl dimethylglycinate;

(R)-4-(8-fluoro-7-(((1S,2S)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-(((1R,2S)-2-(hydroxymethyl)-2-methylcyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-((1-aminocyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(((1R,2R)-2-((S)-1,2-dihydroxyethyl)cyclopropyl)buta-1,3-diyn- 1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-((3-(2-aminoacetamido)cyclopentyl)buta-1,3-diyn-1-yl)-6-fluoro-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(((1R,2R)-2-(aminomethyl)cyclopropyl)buta-1,3-diyn-1-yl)-6-fluoro-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(6-fluoro-7-(5-hydroxy-5-methylhexa-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(2-fluoro-4-(3-morpholinopropoxy)phenyl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(7-(4-(3-morpholinopropoxy)phenyl)-4-oxoquinazolin-3(4H)-yl)butanamide;

(R)-4-(7-(2-fluoro-4-(2-morpholinoethoxy)phenyl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(2-fluoro-3-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(3-fluoro-4-methoxyphenyl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(4-(dimethylamino)phenyl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-(4-(hydroxymethyl)phenyl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(7-(4-(morpholinomethyl)phenyl)-4-oxoquinazolin-3(4H)-yl)butanamide;

(R)-4-(6-fluoro-4-oxo-7-phenylquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((4-(hydroxymethyl)phenypethynyl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-4-(7-((4-(3-hydroxyoxetan-3-yl)phenypethynyl)-4-oxoquinazolin-3(4H)-yl)-2-methyl-2-(methylsulfonyl)butanamide;

(R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-(7-((4-(morpholinomethyl)phenyethynyl)-4-oxoquinazolin-3(4H)-yl)butanamide;

(R)-4-(7-(((1R*,2R*)-1-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(((1R*,2R*)-1-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-(1-((3-(4-(hydroxyamino)-3-methyl-3-(methylsulfonyl)-4-oxobutyl)-4-oxo-3,4-dihydroquinazolin-7-yl)buta-1,3-diyn-1-yl)cyclopropyl)methyl dihydrogen phosphate;

(R)-4-(7-(5-(dimethylamino)penta-1,3-diyn-1-yl)-6-fluoro-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(7-(((1R*,2R*)-2-fluoro-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

(R)-4-(6-fluoro-7-((1-(hydroxymethyl)cyclobutyl)buta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide; or

(R)-4-(6-fluoro-7-(5-(3-hydroxyoxetan-3-yl)penta-1,3-diyn-1-yl)-4-oxoquinazolin-3(4H)-yl)-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide;

or a salt thereof.

12. The compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof, formulated as a medicament.

13. A pharmaceutical composition comprising, as active principle, the compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

14. A method of preventing or treating a bacterial infection comprising administering a therapeutically effective amount of the compound of formula I as defined in claim 1 to a subject in need thereof.

15. The method according to claim 14 , wherein the bacterial infection is Gram-negative bacterial infection.